Analysis of the main ingredients and pharmacological effects of afatinib (Gitarel)

Afatinib is an oral small molecule tyrosine kinase inhibitor whose main component is afatinib itself. This drug is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that can irreversibly inhibit the activity of EGFR and HER2 family receptors, thereby blocking abnormal signaling pathways and inhibiting tumor cell proliferation and survival. Afatinib is mainly used clinically for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), especially for patients who are resistant or intolerant to conventional first-generation EGFR-TKIs.

In terms of pharmacological effects, afatinib binds to the tyrosine kinase of the EGFR receptor, blocking receptor autophosphorylation and the downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling pathways, thereby inhibiting tumor cell proliferation and promoting apoptosis. Unlike the first-generation reversible EGFR inhibitors, afatinib can irreversibly bind to the target, enhance the inhibitory effect, and also shows certain activity against some tumor cells with T790M drug-resistant mutations, giving it a unique advantage in second-line treatment.

The pharmacokinetic characteristics of afatinib also provide guarantee for its efficacy. It has good oral absorption, stable blood concentration, and a half-life of about 37 hours. It can be administered once a day. The drug is mainly metabolized by the liver and excreted in the feces, and a small amount is excreted in the urine. Therefore, patients with hepatic insufficiency need to use it with caution and adjust the dose when necessary to avoid toxic side effects caused by excessive blood concentration.

In clinical application, afatinib not only inhibits tumor growth, but also delays disease progression and improves patients' progression-free survival (PFS). Common side effects include rash, diarrhea, stomatitis, and onychomycosis, but most can be alleviated by dose adjustment, symptomatic management, and lifestyle intervention. Overall, afatinib provides an effective treatment option for EGFR mutation-positive NSCLC patients through precise targeted inhibition mechanisms, and has significant clinical value in drug resistance management.

Reference materials:https://www.drugs.com/